A systematic review of safety and efficacy of systemic corticosteroids in atopic dermatitis

Publication date: Available online 6 December 2017
Source:Journal of the American Academy of Dermatology
Author(s): Sherry Yu, Aaron M. Drucker, Mark Lebwohl, Jonathan I. Silverberg
BackgroundSystemic corticosteroids are often used to treat atopic dermatitis (AD). However, few studies have assessed the safety and efficacy of systemic corticosteroids in AD.ObjectiveTo systematically review the literature on efficacy and safety of systemic corticosteroid use (oral, intramuscular, and intravenous) in AD.MethodsPubMed, Embase, Medline, Scopus, Web of Science, and Cochrane Library were searched. We included systematic reviews, guidelines, and treatment reviews of systemic corticosteroid use among patients of all ages with a diagnosis of AD (52 reviews and 12 studies).ResultsThere was general consensus in the literature to limit the use of systemic steroids to short courses as a bridge to steroid-sparing therapies. Systemic side effects include growth suppression in children, osteoporosis, osteonecrosis, adrenal insufficiency, Cushing syndrome, hypertension, glucose intolerance, diabetes, gastritis, gastroesophageal reflux, peptic ulcer disease, weight gain, emotional lability, behavioral changes, opportunistic infections, cataracts, glaucoma, myopathy, myalgia, dysaesthesia, pseudotumor cerebri, hyperlipidemia, malignancy, thrombosis, skin atrophy, sleep disturbance, and rebound flaring.LimitationsBaseline clinical severity, corticosteroid delivery and dose, and treatment response were reported incompletely and heterogeneously across studies.ConclusionsEvidence is not strong enough to determine optimal delivery or duration of systemic corticosteroids in AD.